William G. Kaelin, Jr., MD

2020 Plenary Keynote: Tackling Undruggable Oncoproteins: Lessons from the VHL Tumor Suppressor Protein

William G. Kaelin, Jr., MD

2019 Nobel Laureate; Sidney Farber Professor of Medicine, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School; Investigator, Howard Hughes Medical Institute (Co-Founder, Cedilla Therapeutics and Co-Founder, Tango Therapeutics)

Dr. Kaelin received the 2019 Nobel Prize in Physiology or Medicine. Dr. Kaelin is a member of the American Society of Clinical Investigation, the American College of Physicians, the National Academy of Sciences and the National Academy of Medicine.


PANEL DISCUSSION: De-Risking Early Drug Discovery

Moderator: Nadeem Sarwar, PhD
Founder & President, Eisai Center for Genetics Guided Dementia Discovery, Eisai, Inc.

Anthony A. Philippakis, PhD
Chief Data Officer, Data Sciences & Data Engineering, Broad Institute, Venture Partner, GV

Stephen A. Hitchcock, PhD
Head, Research, Takeda Pharmaceuticals, Inc.

Research Continues: Join the Discovery on Target Virtual Community

As the coronavirus situation further develops, the health and well-being of our community remains our top priority. We would never have dreamt our world would be facing such uncertain times. Our team has been working for months behind the scenes planning the 2020 event, monitoring and adapting to these new circumstances. We’re excited we can still support your scientific collaborations – now virtually – this fall.

Discovery on Target (DOT) is the industry’s preeminent event on novel drug targets and technologies for drug discovery professionals. DOT highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents, ranging from biologics to small molecules.

We aim to meet your research needs. Delegates can virtually visit numerous concurrent sessions and – with on-demand access to presentations – benefit even from those you can’t attend live. You can customize your experience further through focused short courses, interactive breakout discussions, and virtual networking options that help you engage with experts and solutions providers from the comfort of home.

What’s New in 2020?

Our 2020 program includes new topics on proteomics, small G proteins, disease modeling, preclinical oncology models and tools, CNS, gene and cell therapy, and biomarkers, plus lead and candidate selection for therapeutic proteins and modality selection for next-generation biotherapeutics to continue our growing coverage of biologics.

Your work is valuable and necessary. We’re here to help that research continue as we welcome you to our 18th annual, virtually enhanced event!

2020 Featured Speakers

Daniel Nomura, PhD
University of California Berkeley

David Langenau, PhD
Massachusetts General Hospital; Harvard Medical School

Gabriela Chiosis, PhD
Sloan Kettering Institute for Cancer Center, Cornell and The Rockefeller University

Guido Zaman, PhD

Jennifer C. Petter, PhD
Arrakis Therapeutics

Jian Jin, PhD
Icahn School of Medicine at Mount Sinai

Marla Weetall, PhD
PTC Therapeutics

Priscilla Yang, PhD
Harvard Medical School

Stewart Fisher, PhD
C4 Therapeutics, Inc.

Terrence P. Kenakin, PhD
University of North Carolina at Chapel Hill

Anna Greka, MD, PhD
BWH/Harvard Medical School/Broad Institute

Lakshmi Krishnan, PhD
National Research Council, Canada

Linda Griffith, PhD
Massachusetts Institute of Technology

Dirk Kessler, PhD
Boehringer Ingelheim

Rebecca A. Taub, MD
Madrigal Pharmaceuticals

Premier Sponsors